This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics

SAVINGS DEADLINE EXPIRES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
12 - 14 Nov 2024
Hamburg, Germany

Nadim Akhtar, PhD
Principal Scientist at AstraZeneca
Speaker

Profile

Nadim Akhtar, Ph.D., is a Senior Principal Scientist in the New Modalities and Parenteral Development Department at AstraZeneca. Nadim has been working for AstraZeneca since 2007. During this time Nadim has worked on both early and late-stage portfolio supporting development and commercialisation of small molecules and new modalities such as oligonucleotides, peptides, polymeric nanoparticles, dendrimers, and mRNA products. Nadim is currently responsible for developing characterisation and control strategies for New Modalities.

Agenda Sessions

  • Terminal Sterilisation of Oligonucleotides

    16:30